Tranexamic Acid Versus Sublingual Misoprostol in Reducing Blood Loss During Elective CS in High Risk Cases

Model scores of the 29,894 trials active now.

Model score 6% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 11% of the time (130 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2020-12-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: intravenousskinlosswomenanemia
  Phrases that lowered it: and safetyefficacy andsafety ofacidthe efficacy
• Sponsor's past termination rate: 0.5% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Minimum age: 20 (lowers risk) · Who can join
• Trials the sponsor started in the prior 2 years: 595 (raises risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports with a death: 9.6% (lowers risk) · Drug's FDA history
• Number of arms: 3 (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Sponsor's past trials: 386 (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 73.1% (lowers risk) · Drug's FDA history
• Blinding: none (raises risk) · Design
• Disease area, neurology: No (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Tranexamic Acid Versus Misoprostol in Reducing Blood Loss in Cesarean Section in Primigravida NCT04635007 · started 2021 · scored riskier than 7% of active trials completed
• Intrauterine Misoprostol Versus Intravenous Oxytocin Infusion During Cesarean Delivery NCT03148574 · started 2017 · scored riskier than 8% of active trials completed
• Combined Use of Oxytocin and Misoprostol Versus Oxytocin Infusion and Misoprostol Alone to Reduce Blood Loss at Cesarean Section NCT01571323 · started 2012 · scored riskier than 11% of active trials completed
• Comparative Study Between the Roles of Intrauterine Misoprostol Versus the Sublingual Route for Prevention of Postpartum Blood Loss in Elective Cesarean Sections NCT06364098 · started 2022 · scored riskier than 3% of active trials completed
• Comparative Study Between Oxytocin Versus Tranexamic Acid and Ethamsylate NCT04656067 · started 2020 · scored riskier than 4% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.